| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mark Sanford, Lesley J Scot. Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS drugs. vol 22. issue 4. 2008-07-10. PMID:18336061. |
intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar i disorder. |
2008-07-10 |
2023-08-12 |
Not clear |
| Mark Sanford, Lesley J Scot. Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS drugs. vol 22. issue 4. 2008-07-10. PMID:18336061. |
an intramuscular formulation of the atypical antipsychotic aripiprazole (abilify) has been developed and is approved in the eu for use in agitation and disturbed behaviour associated with schizophrenia. |
2008-07-10 |
2023-08-12 |
Not clear |
| Mark Sanford, Lesley J Scot. Intramuscular aripiprazole : a review of its use in the management of agitation in schizophrenia and bipolar I disorder. CNS drugs. vol 22. issue 4. 2008-07-10. PMID:18336061. |
intramuscular aripiprazole was more effective than placebo in these patient populations and was noninferior to intramuscular haloperidol in those with agitation associated with schizophrenia and its related disorders. |
2008-07-10 |
2023-08-12 |
Not clear |
| Martin Desseilles, Fernand Mathot, Michel Desseille. Aripiprazole diminishes cannabis use in schizophrenia. The Journal of neuropsychiatry and clinical neurosciences. vol 20. issue 1. 2008-07-02. PMID:18305305. |
aripiprazole diminishes cannabis use in schizophrenia. |
2008-07-02 |
2023-08-12 |
Not clear |
| Rajnish Mag. Proposed strategies for successful clinical management with aripiprazole. Expert opinion on pharmacotherapy. vol 9. issue 8. 2008-06-19. PMID:18473703. |
aripiprazole is an effective medication for treating patients with schizophrenia and bipolar disorder , and as an adjunct in patients with major depressive disorder and an inadequate response to antidepressant treatment, that is generally safe and well tolerated. |
2008-06-19 |
2023-08-12 |
Not clear |
| R E Nordquist, C Risterucci, J L Moreau, M von Kienlin, B Künnecke, M Maco, C Freichel, C Riemer, W Spoore. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology. vol 54. issue 2. 2008-05-12. PMID:18054053. |
aripiprazole (opc-14597) is an antipsychotic with a unique pharmacology as a dopamine d2 receptor partial agonist, which has been demonstrated to reduce symptoms of schizophrenia. |
2008-05-12 |
2023-08-12 |
rat |
| J Bhattacharjee, H G G El-Saye. Aripiprazole versus typicals for schizophrenia. The Cochrane database of systematic reviews. issue 1. 2008-04-14. PMID:18254107. |
aripiprazole versus typicals for schizophrenia. |
2008-04-14 |
2023-08-12 |
Not clear |
| Noah S Philip, Linda L Carpenter, Audrey R Tyrka, Lawrence H Pric. Augmentation of antidepressants with atypical antipsychotics: a review of the current literature. Journal of psychiatric practice. vol 14. issue 1. 2008-04-02. PMID:18212601. |
aripiprazole has recently received an indication from the u.s. food and drug administration (fda) for adjunctive treatment in unipolar, nonpsychotic depression, the first indication of its kind, after two double-blind trials; doses were slightly lower than those recommended for monotherapy in schizophrenia or bipolar disorder. |
2008-04-02 |
2023-08-12 |
Not clear |
| Rosaria Di Lorenzo, Alessandra Amoretti, Matilde Forghieri, Fiorenza Fiorini, Susanna Genedani, Marco Rigatell. Aripiprazole: effectiveness and safety under naturalistic conditions. Experimental and clinical psychopharmacology. vol 15. issue 6. 2008-03-17. PMID:18179310. |
a retrospective study was conducted to examine aripiprazole's effectiveness and safety in a naturalistic treatment setting in both inpatients and outpatients affected by schizophrenia and other psychotic disorders. |
2008-03-17 |
2023-08-12 |
Not clear |
| Milena Pereira Pondé, Camila Marinho Novae. Aripiprazole worsening positive symptoms and memantine reducing negative symptoms in a patient with paranoid schizophrenia. Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999). vol 29. issue 1. 2008-03-13. PMID:17435943. |
aripiprazole worsening positive symptoms and memantine reducing negative symptoms in a patient with paranoid schizophrenia. |
2008-03-13 |
2023-08-12 |
Not clear |
| Mark Sanford, Gillian M Keatin. Aripiprazole: in adolescents with schizophrenia. Paediatric drugs. vol 9. issue 6. 2008-02-25. PMID:18052412. |
aripiprazole: in adolescents with schizophrenia. |
2008-02-25 |
2023-08-12 |
Not clear |
| Mark Sanford, Gillian M Keatin. Aripiprazole: in adolescents with schizophrenia. Paediatric drugs. vol 9. issue 6. 2008-02-25. PMID:18052412. |
aripiprazole is a novel atypical antipsychotic that is approved in the us for use in adolescents with schizophrenia. |
2008-02-25 |
2023-08-12 |
Not clear |
| Robert Kerwin, Bruno Millet, Erik Herman, Csaba M Banki, Henrik Lublin, Miranda Pans, Linda Hanssens, Gilbert L'Italien, Robert D McQuade, Jean-Noël Beuze. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study. European psychiatry : the journal of the Association of European Psychiatrists. vol 22. issue 7. 2008-02-19. PMID:17555947. |
a multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients schizophrenia trial of aripiprazole: (star) study. |
2008-02-19 |
2023-08-12 |
Not clear |
| Yoshihiro Tadori, Hisashi Kitagawa, Robert A Forbes, Robert D McQuade, Arlene Stark, Tetsuro Kikuch. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. European journal of pharmacology. vol 574. issue 2-3. 2008-01-17. PMID:17692841. |
aripiprazole is the first dopamine d(2) receptor partial agonist approved for use in schizophrenia and bipolar disorder. |
2008-01-17 |
2023-08-12 |
human |
| Dan Zimbroff, Lewis Warrington, Antony Loebel, Ruoyong Yang, Cynthia Si. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. International clinical psychopharmacology. vol 22. issue 6. 2008-01-14. PMID:17917555. |
comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. |
2008-01-14 |
2023-08-12 |
Not clear |
| Dan Zimbroff, Lewis Warrington, Antony Loebel, Ruoyong Yang, Cynthia Si. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. International clinical psychopharmacology. vol 22. issue 6. 2008-01-14. PMID:17917555. |
we compared the efficacy and safety of ziprasidone and aripiprazole in the treatment of acutely ill patients with schizophrenia. |
2008-01-14 |
2023-08-12 |
Not clear |
| Dan Zimbroff, Lewis Warrington, Antony Loebel, Ruoyong Yang, Cynthia Si. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study. International clinical psychopharmacology. vol 22. issue 6. 2008-01-14. PMID:17917555. |
our findings suggest that ziprasidone and aripiprazole exhibit similar efficacy and tolerability profiles in the treatment of acute schizophrenia. |
2008-01-14 |
2023-08-12 |
Not clear |
| Del D Miller, James M Eudicone, Andrei Pikalov, Edward Ki. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. The Journal of clinical psychiatry. vol 68. issue 12. 2008-01-10. PMID:18162021. |
comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. |
2008-01-10 |
2023-08-12 |
Not clear |
| Del D Miller, James M Eudicone, Andrei Pikalov, Edward Ki. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. The Journal of clinical psychiatry. vol 68. issue 12. 2008-01-10. PMID:18162021. |
to comparatively assess the incidence of tardive dyskinesia in patients with schizophrenia receiving either aripiprazole or haloperidol. |
2008-01-10 |
2023-08-12 |
Not clear |
| R Kaddurah-Daouk, J McEvoy, R A Baillie, D Lee, J K Yao, P M Doraiswamy, K R R Krishna. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Molecular psychiatry. vol 12. issue 10. 2008-01-04. PMID:17440431. |
lipid profiles were derived for 50 patients with schizophrenia before and after treatment for 2-3 weeks with olanzapine (n=20), risperidone (n=14) or aripiprazole (n=16). |
2008-01-04 |
2023-08-12 |
Not clear |